GlassScriptPhysician profile
Sidney Benjamin Zeichner
NPI 1700347499
$2,532.03
in general payments reported to CMS, 2019-2025
21 companies · $1,290 in 2025
The $1,290 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $207 · 2023: $643 · 2024: $392 · 2025: $1,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,305 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,305.18 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $572.90 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $492.41 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $200.78 | 2025 | Repatha, Otezla |
| Abbvie INC. | $191.16 | 2024-2025 | |
| Tris Pharma INC | $185.85 | 2023-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Dexcom, INC. | $146.98 | 2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $121.52 | 2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $120.99 | 2023 | |
| Exact Sciences Corporation | $118.15 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $61.84 | 2023-2025 | Freestyle Libre 3 |
| Myriad Women'S Health, INC. | $58.57 | 2023 | Myrisk |
| Glaxosmithkline, LLC. | $44.12 | 2025 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $37.26 | 2023-2025 | |
| Astellas Pharma US INC | $36.10 | 2025 | Veozah |
| Supernus Pharmaceuticals, INC. | $32.62 | 2024 | Qelbree |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $31.32 | 2023-2025 | Mounjaro, Zepbound |
| Ibsa Pharma INC. | $20.70 | 2025 | Licart, Flector, Tirosint |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.28 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.02 | 2025 | Xifaxan |
| Sumitomo Pharma America, INC. | $14.27 | 2025 | Gemtesa |
| Antares Pharma, INC. | $14.19 | 2025 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sidney Zeichner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.